Article Text

Download PDFPDF
Neither inadequacy of biopsy nor inaccuracy of reporting predict non-response to small-cell carcinoma chemotherapy
  1. T N Doig1,
  2. W A Wallace1,
  3. D M Salter1,
  4. H Monaghan1,
  5. E Brown2
  1. 1Department of Laboratory Services (Pathology), Royal Infirmary of Edinburgh, Edinburgh, UK
  2. 2Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK
  1. Correspondence to:
 H Monaghan
 Department of Laboratory Services (Pathology), Royal Infirmary of Edinburgh, 51 Little France Crescent, Little France, Edinburgh EH16 4SA, UK;hannah.monaghan{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Lung cancer is the second most common cancer in the UK, accounting for one in seven new cancer diagnoses and 22% of cancer deaths ( Small-cell carcinoma (SCC) accounts for 20% of lung cancers, with most of these presenting at an advanced stage and being treated using chemotherapy and radiotherapy. About 25% of patients do not respond to chemotherapy. The reasons for this are uncertain and may be because of the heterogeneity of the disease or inaccurate pathological diagnosis, which …

View Full Text


  • Competing interests: None declared.